Hemophilia gene therapy registry for people already treated
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is a registry that collects health information from people with hemophilia who have already received gene therapy. It helps researchers and clinicians understand how gene therapy affects patients over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of hemophilia
- You have already received a gene therapy treatment for hemophilia
- There are no listed extra health or medication restrictions in the criteria provided
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial is checking how safe and effective two gene therapies are for people with hemophilia A or hemophilia B. It only includes people who already received the study medicines through specific Pfizer studies, so it’s mainly for that existing participant group.
This trial is a research registry that enrolls children with hemophilia A or B to collect health information. It may help researchers better understand bleeding risk and treatment needs over time.
This trial asks people with hemophilia who previously received certain gene therapies to have a liver biopsy. The goal is to improve understanding of how the gene therapy affects the liver and to support safer future care.
This Phase 1 trial tests a gene therapy given with an “own blood stem cell” transplant to improve hemophilia A. It’s mainly to check safety and early signs of how well the therapy works in people with severe bleeding problems.
This trial tests a one-time gene therapy treatment (GS001) to help people with hemophilia A make more of the clotting factor they lack. If it works and is safe for you, it could improve how well blood clots form over time.
This trial tests a new gene therapy (REGV131-LNP1265) that aims to let your body produce its own factor IX, reducing or stopping the need for regular infusions. It is for children and adults with severe hemophilia B who are already using factor IX replacement therapy.
Hear when a new Hemophilia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.